Teva Pharmaceutical Industries Limited
TEVA
$36.77
$0.250.69%
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 706.00M | 1.56B | 1.41B | 712.00M | -158.00M |
| Total Depreciation and Amortization | 989.00M | 999.00M | 1.00B | 1.01B | 1.02B |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.32B | 436.00M | 604.00M | 1.18B | 1.49B |
| Change in Net Operating Assets | -1.11B | -1.29B | -1.37B | -1.84B | -964.00M |
| Cash from Operations | 1.90B | 1.71B | 1.65B | 1.07B | 1.39B |
| Capital Expenditure | -550.00M | -542.00M | -501.00M | -488.00M | -500.00M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -696.00M | -- | -- | 0.00 | 0.00 |
| Divestitures | 54.00M | 59.00M | 34.00M | 38.00M | 68.00M |
| Other Investing Activities | 1.23B | 1.25B | 1.20B | 1.22B | 1.34B |
| Cash from Investing | 38.00M | 765.00M | 737.00M | 774.00M | 907.00M |
| Total Debt Issued | 0.00 | 2.31B | 2.31B | 2.31B | 2.31B |
| Total Debt Repaid | -474.00M | -2.77B | -4.12B | -4.80B | -4.35B |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 73.00M | 75.00M | -337.00M | -366.00M | -364.00M |
| Cash from Financing | -401.00M | -394.00M | -2.15B | -2.87B | -2.41B |
| Foreign Exchange rate Adjustments | -41.00M | -41.00M | 21.00M | -90.00M | 19.00M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1.49B | 2.04B | 256.00M | -1.12B | -96.00M |